Capital Increase in Genmab as a Result of Employee Warrant Exercise

by NASDAQ Market News November 10, 2020

NASDAQ Market News
Click here to email author

Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH

CoImmune, Inc. Announces Closing of $45 Million Series A Financing

Ads